华东医药：2021年第一季度报告全文（英文版）.PDF

《华东医药：2021年第一季度报告全文（英文版）.PDF》由会员分享，可在线阅读，更多相关《华东医药：2021年第一季度报告全文（英文版）.PDF（38页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 1 Huadong Medicine Co., Ltd. The First Quarterly Report 2021 April 2021 The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 2 Section I Important Declaration The Board of Directors, Board of Supervisors, directors, supervisors a

2、nd senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions, and shall undertake individual

3、and joint legal liabilities. All directors have attended the board of directors meeting to review this quarterly report. Lv Liang, the Companys legal representative and the officer in charge of accounting, and Qiu Renbo, head of accounting department (accounting supervisor) hereby declare and guaran

4、tee that the financial statements in this quarterly report are authentic, accurate and complete. According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese or other language version of public notice, they should ensure the content of both versions are th

5、e same. In the case of discrepancy, the original version in Chinese shall prevail. The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 3 Section II Company Profile I. Key Accounting Data and Financial Indicators Whether the Company needs to perform retroactive adjustment or restatement of

6、previous accounting data Yes No The current reporting period Same period last year Change of the current reporting period over the same period last year Operating revenue (yuan) 8,896,632,277.36 8,598,069,911.29 3.47% Net profit attributable to shareholders of listed companies (yuan) 758,380,756.56

7、1,147,278,457.64 -33.90% Net profit attributable to shareholders of listed companies after deducting non-recurring gains/losses (yuan) 695,792,411.78 856,930,262.10 -18.80% Net cash flow from operating activities (yuan) 302,314,164.48 218,779,623.89 38.18% Basic earnings per share (yuan/share) 0.433

8、4 0.6557 -33.90% Diluted earnings per share (yuan/share) 0.4334 0.6557 -33.90% Weighted average return on equity (ROE) 5.04% 8.89% -3.85% End of the current reporting period End of last year Change of the end of the current reporting period over the end of last year Total assets (yuan) 26,096,806,58

9、5.74 24,201,348,154.75 7.83% Net assets attributable to shareholders of listed companies (yuan) 15,266,793,123.79 14,619,821,308.60 4.43% Items and amounts of non-recurring gains/losses Applicable N/A Unit: RMB yuan Item Amount (from the beginning of the year to the end of the reporting period) Note

10、 Gains/losses on disposal of non-current assets (including the written-off part of the accrued assets impairment reserve) 15,675.63 Government grants included in current gains/losses (excluding those closely related to operating activities, or regular government grants) 76,459,624.41 The First Quart

11、erly Report 2021 of Huadong Medicine Co., Ltd. 4 Other non-operating income or expenditure -2,351,230.65 Less: Amount affected by income tax 11,433,797.38 Amount affected by minority interest (after tax) 101,927.23 Total 62,588,344.78 - If the Company recognizes an item as a non-recurring gain/loss

12、based on the “Interpretation Announcement on Information Disclosure Criteria for Public Companies No. 1 Non-Recurring Profit/Loss” or recognizes an item satisfying the definition of non-recurring profit/loss in the announcement as a recurring profit/loss, reasons should be specified. Applicable N/A

13、No such case during the reporting period. II. Total number of shareholders at the end of the reporting period and information of top 10 shareholders 1. Total number of shareholders of common shares and number of shareholders of preferred shares with voting rights restored, as well as information abo

14、ut top 10 shareholders Unit: share Total number of shareholders of common shares at the end of the reporting period 168,355 Total number of shareholders of preferred shares whose voting rights have been restored at the end of the reporting period (if any) 0 Information about top 10 shareholders Name

15、 Nature Shareholding ratio Number of shares held Number of shares held with sale restrictions Pledged or frozen Status Number China Grand Enterprises, Inc. Domestic non-state-owned legal person 41.77% 730,938,157 0 Pledged 239,970,000 Hangzhou Huadong Medicine Group Co., Ltd. State-owned legal perso

16、n 15.69% 274,620,000 0 Hong Kong Securities Clearing Company Ltd. Overseas legal person 1.82% 31,905,503 0 China Securities Finance Co., Ltd. Other 1.27% 22,186,818 0 Huaxia Life Insurance Co., Ltd. - own funds Other 0.61% 10,713,280 0 National Social Other 0.45% 7,926,311 0 The First Quarterly Repo

17、rt 2021 of Huadong Medicine Co., Ltd. 5 Security Fund Portfolio 602 National Social Security Fund Portfolio 503 Other 0.34% 6,000,000 0 Basic Endowment Insurance Fund Portfolio 15041 Other 0.30% 5,253,350 0 #Yang Yushan Domestic individual 0.29% 5,000,000 0 #Chen Shaoming Domestic individual 0.22% 3

18、,764,388 0 Shares held by the top 10 shareholders of Non- restricted shares Name Number of shares held without sale restrictions Type of shares Type Number China Grand Enterprises, Inc. 730,938,157 RMB common shares 730,938,157 Hangzhou Huadong Medicine Group Co., Ltd. 274,620,000 RMB common shares

19、274,620,000 Hong Kong Securities Clearing Company Ltd. 31,905,503 RMB common shares 31,905,503 China Securities Finance Co., Ltd. 22,186,818 RMB common shares 22,186,818 Huaxia Life Insurance Co., Ltd. - own funds 10,713,280 RMB common shares 10,713,280 National Social Security Fund Portfolio 602 7,

20、926,311 RMB common shares 7,926,311 National Social Security Fund Portfolio 503 6,000,000 RMB common shares 6,000,000 Basic Endowment Insurance Fund Portfolio 15041 5,253,350 RMB common shares 5,253,350 #Yang Yushan 5,000,000 RMB common shares 5,000,000 #Chen Shaoming 3,764,388 RMB common shares 3,7

21、64,388 Notes on relations and concerted actions among the shareholders mentioned above The Company does not know whether the shareholders mentioned above are related parties with each other or whether they are acting-in-concert parties with each other. Notes on financing and securities Hangzhou Huad

22、ong Medicine Group Co., Ltd., the second largest shareholder of the The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 6 loan conducted by top 10 shareholders (if any) Company, holds 288,000,000 shares of the Company, accounting for 16.46% of the total capital stock of the Company. As of

23、the end of the reporting period, 13,380,000 shares of the Company have been transferred to China Securities Finance Corporation for loan. At the end of the current reporting period, Yang Yushan, the ninth shareholder of the Company, held 5,000,000 shares of the Company through financing and securiti

24、es loan, Chen Shaoming, the tenth shareholder of the Company, held 3,651,388 shares of the Company through financing and securities loan. Does any of the Companys top 10 shareholders of common shares or top 10 shareholders without sale restrictions on common shares conduct any agreed repurchase tran

25、saction during the reporting period? Yes No No such case during the reporting period. 2. Total number of shareholders of preferred shares and information about top 10 shareholders of preferred shares Applicable N/A The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 7 Section III Substanti

26、al Matters I. Changes in key financial data and financial indicators during the reporting period and their causes Applicable N/A Unit: RMB yuan Balance sheet item End of the period Beginning of the period Change rate Notes on cause of changes Accounts receivable financing 578,065,866.37 828,659,217.

27、25 -30.24% Mainly due to the increase of notes collection in the current period Advance receipts 356,122,946.06 250,916,482.07 41.93% Mainly due to the increase of prepayment Other receivables 116,804,796.17 83,073,823.45 40.60% Mainly due to the increase in provisional payments receivable Other cur

28、rent assets 51,201,382.80 85,654,691.58 -40.22% Mainly due to the decrease of input VAT to be deducted at the end of the period Other non current assets 931,645,777.92 712,069,194.08 30.84% Mainly due to the increase in the prepayment of equipment purchase and intangible assets purchase at the end o

29、f the period Notes payable 981,406,149.63 554,336,058.71 77.04% Mainly due to the increase of bill payment in the current period Long term loan 209,937,945.01 151,611,367.86 38.47% Mainly due to the increase of long-term loans obtained in the current period Income statement item Amount of the curren

30、t period Amount of the previous period Change rate Notes on cause of changes Management expenses 277,542,542.53 196,704,190.05 41.10% Mainly due to the low base in the same period of last year and the increase of salary in the current period Financial expenses 8,531,468.21 15,759,648.63 -45.87% Main

31、ly due to the increase of interest income and the decrease of financing cost Gains on assets disposal 304,336.80 306,269,024.44 -99.90% Mainly due to the transfer of market distribution rights of related products in Western Europe by Sinclair, a wholly owned subsidiary of the Company in the UK Mainl

32、y due to the disposal of the distribution rights and interests in the Western European market of related products of Sinclair, a British wholly-owned subsidiary of the company, in the same period of last year investment income -26,664,999.81 -1,256,335.99 -2022.44% Mainly due to the increase of disc

33、ount interest and The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 8 the decrease of net profit of joint ventures in the current period Other income 76,459,624.41 20,044,478.23 281.45% Mainly due to the increase of government subsidies Net profit 774,473,984.45 1,153,425,789.92 -32.85%

34、Mainly due the higher income from asset disposal of subsidiaries in the same period of last year and the decrease of gross profit of subsidiaries affected by policies in the current period Cash flow statement item Amount of the current period Amount of the previous period Change rate Notes on cause

35、of changes Net cash flows from operating activities 302,314,164.48 218,779,623.89 38.18% Mainly due to the increase of the collection in the current period Net cash flows from investing activities -486,980,878.94 -21,112,417.22 -2206.1% Mainly due to the increase of equity investment funds in the cu

36、rrent period and the transfer of distribution rights and interests of related products in Western European market of Sinclair, a wholly-owned subsidiary of the company in the previous period II. Progress and influence of significant events, and explanatory notes of corresponding solutions Applicable

37、 N/A Implementation progress of share repurchase Applicable N/A Progress in the implementation of reducing repurchased shares by centralized price bidding Applicable N/A III. Unfulfilled and overdue commitments from the related committed parties such as the Companys actual controller, shareholders,

38、related parties, acquirer(s), and the Company during the reporting period Applicable N/A No such case during the reporting period. IV. Financial assets investment 1、Securities investment Applicable N/A Unit: RMB yuan Type of stock Stock code Stock for short Initial investment cost Accounting measure

39、ment Book value at the beginniProfit and loss from fair Accumulative fair value Purchase amount in the current Selling amount in the current Gain/loss during the Book value at the end of the Accounting item Capital source The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 9 model ng of th

40、e period value changes in the current period changes included in equity period period reporting period period Domestic and overseas stock RAPT RAPT 20,207,400.00 Fair value measurement 23,582,877.56 3,113,977.59 3,113,977.59 0.00 0.00 0.00 26,696,855.15 Other equity instruments investment Own funds

41、Total 20,207,400.00 - 23,582,877.56 3,113,977.59 3,113,977.59 0.00 0.00 0.00 26,696,855.15 - - Date of announcement of the board of directors on securities investment approval N/A Date of announcement of the board of shareholders on securities investment approval (if any) N/A Notes: In 2019, Huadong

42、 Medicine Investment Holding (Hong Kong) Co., Ltd., a subsidiary of the company, invested USD 3 million to purchase 218102 series C-2 preferred shares of RAPT therapeutics, Inc. RAPT therapeutics, Inc was listed on Nasdaq Stock Exchange on October 30, 2019 (Stock Code: RAPT). As of the end of the re

43、porting period, Huadong Medicine Investment Holding (Hong Kong) Co., Ltd. held 183002 shares, accounting for 0.74% of the total shares of RAPT therapeutics, Inc. 2、Derivatives investment Applicable N/A No derivative investment during the reporting period. V. Progress of investment projects with rais

44、ed funds Applicable N/A VI. Forecast of business performance from January to June in 2021 Warning and explanation of the reason that the accumulated net profit from the beginning of the year to the end of the next reporting period may be a loss or a substantial change compared with the same period o

45、f the previous year Applicable N/A The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 10 VII. Major contracts for daily operation Applicable N/A VIII. Entrusted financial management Applicable N/A No entrusted financial management during the reporting period. IX. Illegal external guarante

46、e Applicable N/A No illegal external guarantee during the reporting period. X. Non operating capital occupation of listed companies by controlling shareholders and their related parties Applicable N/A No non operating capital occupation of listed companies by controlling shareholders and their relat

47、ed parties during the reporting period. . Registration form of receptions, including research, communication and interview, undertaken during the reporting period Applicable N/A Date Place Method Type of visitor Reception target Main contents of discussion and materials provided Index of basic infor

48、mation of the research February 18, 2021 Company conference room Communication by phone Institution CICC etc. Huadong Medicines self-immunity innovative drug introduction and overseas medical beauty energy source company acquisition investor exchange meeting Please refer to the Record of Investor Re

49、lations Activities on February 18, 2021 published by the company on the Shenzhen Stock Exchange Interactive Easy website and for details. February 25, 2021 Company conference room Communication by phone Institution Haitong Pharmaceutical, Huatai Securities, etc. Investor Exchange Meeting Please refe

50、r to the Record of Investor Relations Activities on February 25, 2021 The First Quarterly Report 2021 of Huadong Medicine Co., Ltd. 11 . Overview of the Companys operations in the first quarter of 2021 （1）Overview of operations During the reporting period, the Company achieved an operating revenue o